Carlyle Group’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

Carlyle Group’s Portfolio OCDX Stock Details OCDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-118,106,000	Closed	-$2.2B	–	10
2022 Q1	$2.2B	Hold	118,106,000	–	–	26.36%	3
2021 Q4	$2.53B	Hold	118,106,000	–	–	26.25%	3
2021 Q3	$2.18B	Sell	118,106,000 -25,300,000	-18%	-$509M	17.27%	4
2021 Q2	$3.07B	Hold	143,406,000	–	–	20.78%	3
2021 Q1	$2.77B	Buy	+143,406,000	New	+$2.53B	20.94%	3

Other funds holding OCDX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Carlyle Group's OCDX Position: Q2 2022 in Review

Carlyle Group sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 118,106,000 shares — an estimated $2.2B sold.

Carlyle Group first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $3.07B in Q2 2021. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

Carlyle Group reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Carlyle Group sold 118,106,000 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $2.2B.
Carlyle Group first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 5 quarters.
Carlyle Group's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $3.07B in Q2 2021.
1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on Carlyle Group's 13F filing for Q2 2022, filed 12 Aug 2022.